{"id":"icotinib","rwe":[{"pmid":"41815163","year":"2026","title":"A case report of idiopathic pulmonary fibrosis concurrent with EGFR 19 deletion lung adenocarcinoma.","finding":"","journal":"Translational cancer research","studyType":"Clinical Study"},{"pmid":"41736521","year":"2026","title":"Epidermal growth factor receptor tyrosine kinase inhibitor for the treatment of non-small cell lung cancer in the past 30 years (1997-2026).","finding":"","journal":"Chinese medical journal","studyType":"Clinical Study"},{"pmid":"41729955","year":"2026","title":"Efficacy and Safety of Aumolertinib/Icotinib Combination Therapy for Naive EGFR-Mutant NSCLC Patients with Brain Metastases: A Phase I/II Study.","finding":"","journal":"Neuro-oncology","studyType":"Clinical Study"},{"pmid":"41707781","year":"2026","title":"Economic value, affordability, and scale-up of adjuvant immunotherapies in lung cancer treatment: From cost-effectiveness decision to budget impact analysis.","finding":"","journal":"Journal of cancer policy","studyType":"Clinical Study"},{"pmid":"41622936","year":"2025","title":"[A Case of Refractory Pulmonary Enteric Adenocarcinoma with EGFR Sensitive Mutation].","finding":"","journal":"Zhongguo fei ai za zhi = Chinese journal of lung cancer","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Epidermal growth factor receptor","category":"target"},{"label":"EGFR","category":"gene"},{"label":"STK10","category":"gene"},{"label":"CARS","category":"gene"},{"label":"L01EB08","category":"atc"},{"label":"Active","category":"status"},{"label":"Non-small cell lung cancer","category":"indication"},{"label":"Zhejiang Beta Pharma Inc.","category":"company"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"Zhejiang Beta Pharma Inc.","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ICOTINIB","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:10:42.037340+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:10:48.230029+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ICOTINIB","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:10:48.600602+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Epidermal growth factor receptor erbB1 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:10:49.649409+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2087361/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:10:49.302399+00:00"}},"allNames":["icotinib","icotinib hydrochloride"],"offLabel":[],"synonyms":["icotinib","icotinib hydrochloride"],"timeline":[],"approvals":[{"date":"","orphan":false,"company":"Zhejiang Beta Pharma Inc.","regulator":"China Food and Drug Administration (CFDA)"}],"ecosystem":[{"indication":"Non-small cell lung cancer","otherDrugs":[{"name":"alectinib","slug":"alectinib","company":"Hoffman-La Roche"},{"name":"brigatinib","slug":"brigatinib","company":"Ariad"},{"name":"ceritinib","slug":"ceritinib","company":"Novartis Pharms Corp"},{"name":"crizotinib","slug":"crizotinib","company":"Pf Prism Cv"}],"globalPrevalence":2200000}],"mechanism":{"target":"Epidermal growth factor receptor","targets":[{"gene":"EGFR","source":"DrugCentral","target":"Epidermal growth factor receptor","protein":"Epidermal growth factor receptor"},{"gene":"STK10","source":"DrugCentral","target":"Serine/threonine-protein kinase 10","protein":"Serine/threonine-protein kinase 10"},{"gene":"CARS","source":"DrugCentral","target":"Cysteine--tRNA ligase, cytoplasmic","protein":"Cysteine--tRNA ligase, cytoplasmic"},{"gene":"GAK","source":"DrugCentral","target":"Cyclin-G-associated kinase","protein":"Cyclin-G-associated kinase"},{"gene":"SLK","source":"DrugCentral","target":"STE20-like serine/threonine-protein kinase","protein":"STE20-like serine/threonine-protein kinase"},{"gene":"RIPK2","source":"DrugCentral","target":"Receptor-interacting serine/threonine-protein kinase 2","protein":"Receptor-interacting serine/threonine-protein kinase 2"},{"gene":"BUB1","source":"DrugCentral","target":"Mitotic checkpoint serine/threonine-protein kinase BUB1","protein":"Mitotic checkpoint serine/threonine-protein kinase BUB1"},{"gene":"MAP3K1","source":"DrugCentral","target":"Mitogen-activated protein kinase kinase kinase 1","protein":"Mitogen-activated protein kinase kinase kinase 1"},{"gene":"PIP4K2C","source":"DrugCentral","target":"Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma","protein":"Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma"}],"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Icotinib is a competitive inhibitor of the EGFR tyrosine kinase, which is a crucial enzyme in the signaling pathway that regulates cell proliferation and survival."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5209","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ICOTINIB","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ICOTINIB","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T14:57:43.767301","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:10:50.915619+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"gefitinib","drugSlug":"gefitinib","fdaApproval":"2003-05-05","genericCount":5,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"erlotinib","drugSlug":"erlotinib","fdaApproval":"2004-11-18","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"afatinib","drugSlug":"afatinib","fdaApproval":"2013-07-12","patentExpiry":"Oct 10, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"osimertinib","drugSlug":"osimertinib","fdaApproval":"2015-11-13","patentExpiry":"Nov 26, 2042","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"dacomitinib","drugSlug":"dacomitinib","fdaApproval":"2018-09-27","patentExpiry":"Sep 27, 2032","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"mobocertinib","drugSlug":"mobocertinib","fdaApproval":"2021-09-15","patentExpiry":"May 13, 2035","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"icotinib","indications":{"approved":[{"name":"Non-small cell lung cancer","source":"DrugCentral","snomedId":254637007,"regulator":"FDA","usPrevalence":236000,"globalPrevalence":2200000,"prevalenceMethod":"curated","prevalenceSource":"IARC GLOBOCAN, 2022"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"gefitinib","brandName":"gefitinib","genericName":"gefitinib","approvalYear":"2003","relationship":"same-class"},{"drugId":"erlotinib","brandName":"erlotinib","genericName":"erlotinib","approvalYear":"2004","relationship":"same-class"},{"drugId":"afatinib","brandName":"afatinib","genericName":"afatinib","approvalYear":"2013","relationship":"same-class"},{"drugId":"osimertinib","brandName":"osimertinib","genericName":"osimertinib","approvalYear":"2015","relationship":"same-class"},{"drugId":"dacomitinib","brandName":"dacomitinib","genericName":"dacomitinib","approvalYear":"2018","relationship":"same-class"},{"drugId":"mobocertinib","brandName":"mobocertinib","genericName":"mobocertinib","approvalYear":"2021","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07458919","phase":"EARLY_PHASE1","title":"Therapy for Advanced NSCLC With EGFR 19delins Mutation","status":"NOT_YET_RECRUITING","sponsor":"Fuzhou General Hospital","startDate":"2026-03-30","conditions":["Lung Cancer"],"enrollment":94,"completionDate":"2030-10-30"},{"nctId":"NCT05263947","phase":"PHASE2","title":"Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation","status":"COMPLETED","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2022-01-30","conditions":["Carcinoma, Non-Small-Cell Lung","Bevacizumab","Tyrosine Kinase Inhibitor","EGFR L858R"],"enrollment":35,"completionDate":"2023-12-30"},{"nctId":"NCT04206072","phase":"PHASE2,PHASE3","title":"D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC","status":"COMPLETED","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2019-12-24","conditions":["Non-Small Cell Lung Cancer","EGFR Gene Mutation"],"enrollment":362,"completionDate":"2025-07-15"},{"nctId":"NCT06955325","phase":"PHASE3","title":"Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2025-05","conditions":["Non-Small Cell Lung Cancer"],"enrollment":270,"completionDate":"2035-12"},{"nctId":"NCT02264210","phase":"PHASE2","title":"Icotinib for Completed Resected IB NSCLC With EGFR Mutation","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2015-01","conditions":["Lung Neoplasms","Squamous Cell Lung Cancer","Adenocarcinoma of the Lung","Adenosquamous Cell Lung Cancer","Large Cell Lung Cancer","Bronchial Neoplasms","Stage IB Non-small Cell Lung Cancer"],"enrollment":128,"completionDate":"2022-07"},{"nctId":"NCT01996098","phase":"PHASE3","title":"Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR Mutation","status":"TERMINATED","sponsor":"Sun Yat-sen University","startDate":"2014-01-01","conditions":["Lung Cancer"],"enrollment":251,"completionDate":"2024-02-15"},{"nctId":"NCT05007938","phase":"PHASE2","title":"Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2021-08-12","conditions":["Non-Small Cell Lung Cancer"],"enrollment":30,"completionDate":"2024-12-31"},{"nctId":"NCT06517953","phase":"PHASE2","title":"Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-07-17","conditions":["Non-small Cell Lung Cancer Metastatic","EGFR G719X","EGFR L861Q","EGFR S768I"],"enrollment":23,"completionDate":"2027-12-24"},{"nctId":"NCT04397432","phase":"","title":"Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Retrospective Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tian Xie","startDate":"2020-08-28","conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":878,"completionDate":"2026-03-30"},{"nctId":"NCT04401059","phase":"PHASE4","title":"Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study","status":"RECRUITING","sponsor":"Tian Xie","startDate":"2020-11-09","conditions":["Carcinoma","Non-Small-Cell Lung Cancer","Adenocarcinoma"],"enrollment":744,"completionDate":"2026-03-30"},{"nctId":"NCT06041776","phase":"PHASE3","title":"Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations","status":"RECRUITING","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2023-03-28","conditions":["Non-Small Cell Lung Cancer","EGFR Sensitive Mutation","Adjuvant Therapy"],"enrollment":570,"completionDate":"2029-11-30"},{"nctId":"NCT01973725","phase":"PHASE2","title":"Study of Icotinib Hydrochloride in Treating Patients With Recurrent or Metastatic Esophageal Cancer After Failure of Conventional Chemotherapy","status":"COMPLETED","sponsor":"Yuhong Li","startDate":"2013-10","conditions":["Esophageal Squamous Cell Carcinoma"],"enrollment":50,"completionDate":"2018-12"},{"nctId":"NCT05536505","phase":"PHASE2","title":"Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC","status":"RECRUITING","sponsor":"Guangdong Association of Clinical Trials","startDate":"2022-09-13","conditions":["MRD"],"enrollment":180,"completionDate":"2030-10-01"},{"nctId":"NCT05514314","phase":"PHASE2","title":"A Multicenter Prospective Study to Assess the Effects of Adjuvant Icotinib in EGFRm Stage I NSCLC With High-risk of Disease Recurrence After Complete Resection","status":"UNKNOWN","sponsor":"Wu Nan","startDate":"2022-09-01","conditions":["Non-Small Cell Lung Cancer"],"enrollment":90,"completionDate":"2025-06-30"},{"nctId":"NCT02044328","phase":"PHASE2","title":"Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation","status":"COMPLETED","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2014-01","conditions":["Non-small Cell Lung Cancer"],"enrollment":79,"completionDate":"2021-10"},{"nctId":"NCT05132985","phase":"PHASE2","title":"Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Liaoning Cancer Hospital & Institute","startDate":"2022-01-01","conditions":["NSCLC","EGF-R Positive Non-Small Cell Lung Cancer"],"enrollment":45,"completionDate":"2028-01-01"},{"nctId":"NCT05104788","phase":"PHASE2","title":"A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2021-10-25","conditions":["Non-Small Cell Lung Cancer"],"enrollment":27,"completionDate":"2026-12-01"},{"nctId":"NCT02934256","phase":"PHASE2","title":"Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors","status":"COMPLETED","sponsor":"Li Peng","startDate":"2016-07","conditions":["Vestibular Schwannoma","Neurofibromatosis Type 2"],"enrollment":10,"completionDate":"2018-07"},{"nctId":"NCT02448797","phase":"PHASE3","title":"Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2015-06-08","conditions":["Non-small Cell Lung Cancer"],"enrollment":320,"completionDate":"2023-12"},{"nctId":"NCT03595644","phase":"PHASE2","title":"Maintenance Targeted Therapy With or Without Stereotactic Body Radiation Therapy for Stage IV Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Tongji Hospital","startDate":"2017-02-12","conditions":["Stage IV Non-small Cell Lung Cancer"],"enrollment":74,"completionDate":"2020-12-10"},{"nctId":"NCT03736837","phase":"PHASE2","title":"Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC","status":"COMPLETED","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2018-12-01","conditions":["Non Small Cell Lung Cancer"],"enrollment":60,"completionDate":"2021-01-01"},{"nctId":"NCT04797806","phase":"PHASE3","title":"Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2021-03-12","conditions":["Non Small Cell Lung Cancer"],"enrollment":206,"completionDate":"2023-04-30"},{"nctId":"NCT02362230","phase":"PHASE2","title":"Evaluation of Icotinib in Metastatic Triple-negative Breast Cancer After Second-line Therapy","status":"TERMINATED","sponsor":"Sun Yat-sen University","startDate":"2015-01","conditions":["Metastatic Breast Cancer"],"enrollment":26,"completionDate":"2020-12-15"},{"nctId":"NCT04575415","phase":"","title":"Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study","status":"UNKNOWN","sponsor":"Guangdong Association of Clinical Trials","startDate":"2020-10-07","conditions":["NSCLC"],"enrollment":272,"completionDate":"2023-12"},{"nctId":"NCT02737774","phase":"PHASE2","title":"Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2016-04-13","conditions":["Lung Adenocarcinoma"],"enrollment":60,"completionDate":"2021-06-01"},{"nctId":"NCT02744664","phase":"PHASE4","title":"Cryotherapy Combine Icotinib for Advanced NSCLC Treatment","status":"COMPLETED","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2016-04-01","conditions":["Lung Neoplasms"],"enrollment":60,"completionDate":"2017-08-15"},{"nctId":"NCT03544814","phase":"PHASE2","title":"EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression","status":"COMPLETED","sponsor":"Shanghai Chest Hospital","startDate":"2015-01-01","conditions":["Lung Adenocarcinoma","EGFR Activating Mutation"],"enrollment":99,"completionDate":"2017-12-30"},{"nctId":"NCT04058704","phase":"PHASE3","title":"A Study to Determine the Efficiency For Brain Metastasis NSCLC Patients Treated With Icotinib Alone or Combined With Radiation Therapy","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2018-07-20","conditions":["Non Small Cell Lung Cancer","Brain Metastases"],"enrollment":296,"completionDate":"2022-12-31"},{"nctId":"NCT01719536","phase":"PHASE3","title":"Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients","status":"COMPLETED","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2012-12","conditions":["NSCLC"],"enrollment":296,"completionDate":"2017-02-07"},{"nctId":"NCT04007835","phase":"NA","title":"Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI","status":"UNKNOWN","sponsor":"Guangdong Association of Clinical Trials","startDate":"2019-07","conditions":["NSCLC"],"enrollment":120,"completionDate":"2021-12"},{"nctId":"NCT01855854","phase":"PHASE2","title":"Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH","status":"COMPLETED","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2013-05","conditions":["Adenocarcinoma of the Gastroesophageal Junction","Esophageal Carcinoma"],"enrollment":54,"completionDate":"2016-01-07"},{"nctId":"NCT03992885","phase":"PHASE3","title":"Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations.","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2019-07-01","conditions":["Non-squamous Non-small Cell Lung Cancer"],"enrollment":70,"completionDate":"2025-08-01"},{"nctId":"NCT03983811","phase":"NA","title":"Adjuvant Chemotherapy With or Without Intercalated Icotinib","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2019-07-01","conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":174,"completionDate":"2025-10-31"},{"nctId":"NCT02889692","phase":"PHASE3","title":"Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma","status":"COMPLETED","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2013-03","conditions":["Cancer"],"enrollment":23,"completionDate":"2017-06-01"},{"nctId":"NCT02726568","phase":"PHASE2","title":"High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2016-03","conditions":["Non-small Cell Lung Cancer","Brain Metastases"],"enrollment":30,"completionDate":"2022-12"},{"nctId":"NCT03766490","phase":"NA","title":"Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2019-03-30","conditions":["Non-Small-Cell Lung"],"enrollment":66,"completionDate":"2020-12-20"},{"nctId":"NCT03754530","phase":"PHASE2","title":"Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2018-12-01","conditions":["Non-Small Cell Lung Cancer","Brain Metastases"],"enrollment":162,"completionDate":"2021-12-01"},{"nctId":"NCT03749213","phase":"PHASE2","title":"Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2018-12-01","conditions":["EGF-R Positive Non-Small Cell Lung Cancer"],"enrollment":36,"completionDate":"2024-12-30"},{"nctId":"NCT03222622","phase":"PHASE2","title":"Study of Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis","status":"TERMINATED","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2017-11-29","conditions":["Mild to Moderate Psoriasis"],"enrollment":136,"completionDate":"2018-10-26"},{"nctId":"NCT03720873","phase":"PHASE2","title":"EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC","status":"UNKNOWN","sponsor":"Fujian Cancer Hospital","startDate":"2018-10","conditions":["EGFR Gene Mutation"],"enrollment":90,"completionDate":"2022-09"},{"nctId":"NCT03634059","phase":"NA","title":"A Study of Apatinib Plus EGFR-TKI as First Line Treatment in Patients With Non-squamous NSCLC Harboring EGFR Mutations","status":"UNKNOWN","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2018-08-15","conditions":["NSCLC"],"enrollment":80,"completionDate":"2020-08-15"},{"nctId":"NCT03349203","phase":"PHASE2","title":"Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2018-10-01","conditions":["EGF-R Positive Non-Small Cell Lung Cancer"],"enrollment":60,"completionDate":"2023-12-30"},{"nctId":"NCT03396185","phase":"PHASE2","title":"Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2018-05-09","conditions":["EGFR Gene Mutation","Non Small Cell Lung Cancer Stage IIIA","Non Small Cell Lung Cancer Stage IIIB"],"enrollment":30,"completionDate":"2023-02-01"},{"nctId":"NCT02125240","phase":"PHASE3","title":"Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2014-09","conditions":["EGFR Positive Non-small Cell Lung Cancer","Adenocarcinoma"],"enrollment":124,"completionDate":"2021-07"},{"nctId":"NCT03151161","phase":"PHASE2","title":"Intermittent and Maintenance of Icotinib in Combination With Pemetrexed/Carboplatin Compared With Icotinib Single Drug in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2015-12","conditions":["Lung, Carcinoma"],"enrollment":118,"completionDate":"2019-05"},{"nctId":"NCT01534585","phase":"PHASE1,PHASE2","title":"Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma","status":"COMPLETED","sponsor":"Taizhou Hospital","startDate":"2012-02","conditions":["Nasopharyngeal Carcinoma"],"enrollment":48,"completionDate":"2015-02"},{"nctId":"NCT03053297","phase":"","title":"Observational Study of Patients With Locally Advanced or Metastatic NSCLC (Non-Small Cell Lung Cancer)","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2017-03-01","conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":89,"completionDate":"2017-11-08"},{"nctId":"NCT03402464","phase":"PHASE2","title":"Icotinib Combined With Dihydroaremisinin (DHA) Therapy in Patients With Advanced NSCLC","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2018-01","conditions":["EGFR Positive Non-Small Cell Lung Cancer,Adenocarcinoma"],"enrollment":30,"completionDate":"2020-09-20"},{"nctId":"NCT03346811","phase":"PHASE2","title":"Efficiency of Icotinib in Plasma ctDNA EGFR Mutation-positive Patients Diagnosed With Lung Cancer","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2017-11-18","conditions":["Plasma EGFR Mutation-positive Lung Cancer"],"enrollment":120,"completionDate":"2020-03-10"},{"nctId":"NCT02714010","phase":"PHASE3","title":"EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLC","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2015-08","conditions":["Non-Small Cell Lung Cancer"],"enrollment":601,"completionDate":"2022-12"},{"nctId":"NCT03258671","phase":"NA","title":"IMRT and Timing in Combination With EGFRTKI for Stage IV Non-small-cell Lung Cancer","status":"UNKNOWN","sponsor":"LuBing","startDate":"2017-10-01","conditions":["Non-Small Cell Lung Cancer","Nonsmall Cell Lung Cancer","Carcinoma, Non-Small-Cell Lung"],"enrollment":160,"completionDate":"2020-12-30"},{"nctId":"NCT02404675","phase":"PHASE4","title":"High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2015-04","conditions":["NSCLC"],"enrollment":240,"completionDate":"2018-09"},{"nctId":"NCT02801435","phase":"PHASE1","title":"Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis","status":"COMPLETED","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2016-09-17","conditions":["Psoriasis"],"enrollment":41,"completionDate":"2017-06-08"},{"nctId":"NCT02574091","phase":"PHASE1","title":"Icotinib Hydrochloride Cream in Healthy Adults and Psoriasis Patients","status":"COMPLETED","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2015-11-26","conditions":["Psoriasis"],"enrollment":28,"completionDate":"2017-02-19"},{"nctId":"NCT03153358","phase":"PHASE2","title":"Icotinib Combined With SBRT for Patients With Metastatic Non-squamous NSCLC With EGFR Mutation","status":"UNKNOWN","sponsor":"Sichuan Cancer Hospital and Research Institute","startDate":"2017-06-02","conditions":["Lung Cancer Stage IV"],"enrollment":60,"completionDate":"2019-05-02"},{"nctId":"NCT01963195","phase":"PHASE2","title":"Evaluation of the High Dose of Icotinib in Advanced Lung Cancer Patients After Failure of Target Therapy","status":"UNKNOWN","sponsor":"Anhui Medical University","startDate":"2014-02","conditions":["NSCLC"],"enrollment":30,"completionDate":"2019-12"},{"nctId":"NCT03123484","phase":"PHASE2","title":"β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC","status":"UNKNOWN","sponsor":"China Medical University, China","startDate":"2017-04","conditions":["Non Small Cell Lung Cancer"],"enrollment":80,"completionDate":"2019-10"},{"nctId":"NCT01724801","phase":"PHASE3","title":"Icotinib or Whole Brain Irradiation in EGFR-mutant Lung Cancer","status":"COMPLETED","sponsor":"Guangdong Association of Clinical Trials","startDate":"2012-10-14","conditions":["Brain Metastasis","Non Small Cell Lung Cancer"],"enrollment":176,"completionDate":"2016-09-14"},{"nctId":"NCT01665417","phase":"PHASE4","title":"Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2012-08","conditions":["EGFR Positive Non-small Cell Lung Cancer","Adenocarcinoma"],"enrollment":100,"completionDate":"2017-12"},{"nctId":"NCT01744925","phase":"PHASE2","title":"Icotinib at Different Doses in Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EGFR","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2012-10","conditions":["Non-small Cell Lung Cancer"],"enrollment":60,"completionDate":"2017-12"},{"nctId":"NCT03008109","phase":"PHASE3","title":"Endostar Plus EGFR-TKI（Epidermal Growth Factor Receptor-Tyrosine-Kinase Inhibitor） as a Treatment of EGFR Mutation-positive NSCLC","status":"UNKNOWN","sponsor":"Zaiwen Fan","startDate":"2017-02","conditions":["Advanced Cancer","Lung Cancer, Nonsmall Cell"],"enrollment":80,"completionDate":"2018-11"},{"nctId":"NCT02787447","phase":"PHASE2","title":"Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy","status":"UNKNOWN","sponsor":"First People's Hospital of Hangzhou","startDate":"2016-05","conditions":["Lung Adenocarcinoma"],"enrollment":46,"completionDate":"2020-05"},{"nctId":"NCT02960607","phase":"PHASE2","title":"High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2016-11","conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":25,"completionDate":""},{"nctId":"NCT02961270","phase":"PHASE2","title":"Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2016-11","conditions":["Non-small Cell Lung Cancer"],"enrollment":30,"completionDate":"2018-08"},{"nctId":"NCT02882984","phase":"PHASE3","title":"Hypofractionated Brain Radiation In EGFR Mutated Adenocarcinoma Cranial Disease (Hybrid)","status":"UNKNOWN","sponsor":"Sichuan Provincial People's Hospital","startDate":"2015-03","conditions":["Stage IV EGFR Mutated NSCL With Brain Metastases"],"enrollment":325,"completionDate":"2020-12"},{"nctId":"NCT02883543","phase":"PHASE3","title":"First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR Mutation","status":"UNKNOWN","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2016-06","conditions":["Non-small Cell Lung Cancer"],"enrollment":330,"completionDate":"2019-06"},{"nctId":"NCT01745302","phase":"","title":"Efficacy Study of Chinese Medicine Plus EGFR-TKI Versus EGFR-TKI in Advanced Pulmonary Adenocarcinoma","status":"UNKNOWN","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2011-11","conditions":["Cancer"],"enrollment":470,"completionDate":"2016-12"},{"nctId":"NCT02820116","phase":"PHASE2","title":"The Role of Icotinib in the Perioperative Treatment of IIIA - IIIB NSCLC Patients With EGFR Mutation","status":"UNKNOWN","sponsor":"Beijing Haidian Hospital","startDate":"2016-05","conditions":["Non-small Cell Lung Cancer(NSCLC)"],"enrollment":67,"completionDate":"2023-04"},{"nctId":"NCT02788058","phase":"PHASE2","title":"A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy","status":"UNKNOWN","sponsor":"First People's Hospital of Hangzhou","startDate":"2016-05","conditions":["Lung Adenocarcinoma","EGFR Positive Non-small Cell Lung Cancer"],"enrollment":76,"completionDate":"2022-05"},{"nctId":"NCT02778893","phase":"PHASE4","title":"Conmana Combined With Thalidomide to Treat NSCLC","status":"UNKNOWN","sponsor":"Henan Provincial People's Hospital","startDate":"2016-03","conditions":["NSCLC"],"enrollment":67,"completionDate":"2020-03"},{"nctId":"NCT02738983","phase":"PHASE2","title":"RT Plus EGFR-TKI for Wild-type NSCLC","status":"UNKNOWN","sponsor":"Hangzhou Cancer Hospital","startDate":"2012-01","conditions":["Non-small Cell Lung Cancer","Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)"],"enrollment":22,"completionDate":"2017-12"},{"nctId":"NCT02031601","phase":"PHASE4","title":"Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2014-01","conditions":["Non-Small-Cell Lung Cancer"],"enrollment":250,"completionDate":"2017-12"},{"nctId":"NCT02375581","phase":"PHASE2","title":"Phase II Study of Icotinib With Concurrent Radiotherapy in Elderly Patients With Esophageal Cancer","status":"UNKNOWN","sponsor":"First People's Hospital of Hangzhou","startDate":"2015-01","conditions":["Esophageal Cancer"],"enrollment":130,"completionDate":"2018-12"},{"nctId":"NCT01646450","phase":"PHASE4","title":"First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2012-07","conditions":["Non-Small Cell Lung Cancer"],"enrollment":35,"completionDate":"2016-04"},{"nctId":"NCT01707329","phase":"PHASE2","title":"Icotinib in Combination With Chemotherapy Versus Chemotherapy Alone in Patients Progressed After Icotinib Treatment","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2012-09","conditions":["Non-small Cell Lung Cancer"],"enrollment":180,"completionDate":"2016-12"},{"nctId":"NCT01926171","phase":"PHASE4","title":"Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain Metastases","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2013-06","conditions":["Non-small-cell Lung Cancer"],"enrollment":80,"completionDate":"2016-12"},{"nctId":"NCT02024633","phase":"PHASE1","title":"Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2013-12","conditions":["Pancreatic Cancer"],"enrollment":24,"completionDate":"2016-03"},{"nctId":"NCT01843647","phase":"PHASE2","title":"Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2013-04","conditions":["Non-small-cell Lung Cancer"],"enrollment":100,"completionDate":"2018-02"},{"nctId":"NCT02062515","phase":"PHASE2","title":"Icotinib in Advanced Non-small Cell Lung Cancer (NSCLC) With Hepatic Insufficiency","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2014-02","conditions":["Non-small Cell Lung Cancer"],"enrollment":30,"completionDate":"2016-06"},{"nctId":"NCT02486354","phase":"PHASE3","title":"Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With Chemotherapy","status":"COMPLETED","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2010-03","conditions":["Non-small Cell Lung Cancer"],"enrollment":128,"completionDate":"2012-04"},{"nctId":"NCT01929200","phase":"PHASE2","title":"Icotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR Mutation","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2013-08","conditions":["Non-small-cell Lung Cancer"],"enrollment":120,"completionDate":"2017-08"},{"nctId":"NCT01720901","phase":"PHASE4","title":"Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy","status":"SUSPENDED","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2013-02","conditions":["Non-small Cell Lung Cancer"],"enrollment":20,"completionDate":"2016-12"},{"nctId":"NCT02027090","phase":"PHASE2","title":"High Dose Versus Routine Dose Icotinib in Advanced Non-small Cell Lung Cancer Patients With Stable Disease","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2014-01","conditions":["Non-small Cell Lung Cancer"],"enrollment":64,"completionDate":"2016-12"},{"nctId":"NCT02278458","phase":"PHASE1","title":"Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2014-10","conditions":["Pancreatic Cancer"],"enrollment":24,"completionDate":"2016-10"},{"nctId":"NCT02430974","phase":"PHASE2","title":"Chemotherapy of NSCLC With or Without Icotinib","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2011-01","conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":50,"completionDate":"2018-01"},{"nctId":"NCT02103257","phase":"PHASE4","title":"Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2014-03","conditions":["EGFR Positive Non-small Cell Lung Cancer","Adenocarcinoma"],"enrollment":192,"completionDate":"2017-09"},{"nctId":"NCT02407366","phase":"PHASE2","title":"Icotinib With Concurrent Radiotherapy vs. Chemoradiotherapy in Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"People's Hospital of Guangxi Zhuang Autonomous Region","startDate":"2014-12","conditions":["Non-small Cell Lung Cancer"],"enrollment":80,"completionDate":"2017-12"},{"nctId":"NCT02375022","phase":"PHASE2","title":"Rh-Endostatin in Combination With Icotinib for Advanced NSCLC With EGFR Mutations","status":"UNKNOWN","sponsor":"Zhejiang University","startDate":"2015-03","conditions":["Lung Cancer"],"enrollment":10,"completionDate":"2016-03"},{"nctId":"NCT02066870","phase":"PHASE1","title":"Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2014-01","conditions":["Non-small Cell Lung Cancer"],"enrollment":9,"completionDate":"2016-01"},{"nctId":"NCT02009605","phase":"PHASE2","title":"Icotinib in Previously Treated Non/Light-smoking Patients With Advanced Squamous Cell Lung Cancer","status":"UNKNOWN","sponsor":"Zhejiang University","startDate":"2015-03","conditions":["Squamous Cell Carcinoma of Lung"],"enrollment":30,"completionDate":"2016-03"},{"nctId":"NCT02328261","phase":"PHASE2","title":"A Phase II Study of Icotinib in Treating Patients With Advanced Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2014-11","conditions":["Nasopharyngeal Carcinoma"],"enrollment":66,"completionDate":"2017-04"},{"nctId":"NCT01690390","phase":"PHASE2","title":"Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2012-09","conditions":["NSCLC"],"enrollment":180,"completionDate":"2016-07"},{"nctId":"NCT02283424","phase":"PHASE4","title":"Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene Mutation","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2014-10","conditions":["Neoplasms, Therapy-Associated"],"enrollment":10,"completionDate":"2017-12"},{"nctId":"NCT02033148","phase":"PHASE1","title":"Icotinib Hydrochloride in Treating Patients With Advanced Cancers","status":"WITHDRAWN","sponsor":"Roswell Park Cancer Institute","startDate":"2014-08","conditions":["Unspecified Adult Solid Tumor, Protocol Specific"],"enrollment":0,"completionDate":""},{"nctId":"NCT02272127","phase":"PHASE2","title":"Study of Chemotherapy Plus Icotinib to Treat EGFR Mutation-positive Non-small-cell Lung Cancer","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2014-07","conditions":["NSCLC"],"enrollment":100,"completionDate":"2019-07"},{"nctId":"NCT02215356","phase":"PHASE2","title":"Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2014-08","conditions":["Non-small Cell Lung Cancer"],"enrollment":120,"completionDate":"2019-02"},{"nctId":"NCT02191059","phase":"PHASE2","title":"Phase II Clinical Study of Intermittent High Dose of Icotinib in Combination With Docetaxel to Treat Lung Cancer","status":"UNKNOWN","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2014-07","conditions":["Non Small Cell Lung Cancer"],"enrollment":60,"completionDate":"2016-07"},{"nctId":"NCT01514877","phase":"PHASE2","title":"Icotinib Combined With Whole Brain Radiotherapy in Treating Multiple Brain Metastases From Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Zhejiang Cancer Hospital","startDate":"2012-01","conditions":["Lung Cancer","Metastatic Cancer"],"enrollment":20,"completionDate":"2014-07"},{"nctId":"NCT02194556","phase":"PHASE4","title":"Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2014-07","conditions":["EGFR Positive Non-small Cell Lung Cancer","Adenocarcinoma"],"enrollment":100,"completionDate":"2017-07"},{"nctId":"NCT01465243","phase":"PHASE4","title":"Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose","status":"COMPLETED","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2011-09","conditions":["Non-small Cell Lung Cancer"],"enrollment":32,"completionDate":"2014-02"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"9G6U5L461Q","UMLSCUI":"C2604307","chemblId":"CHEMBL2087361","ChEMBL_ID":"CHEMBL2087361","DRUGBANK_ID":"DB11737","PUBCHEM_CID":"22024915","IUPHAR_LIGAND_ID":"7641","SECONDARY_CAS_RN":"1204313-51-8","MESH_SUPPLEMENTAL_RECORD_UI":"C531470"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Zhejiang Beta Pharma Inc.","relationship":"Original Developer"}],"publicationCount":431,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"L01EB08","allCodes":["L01EB08"]},"biosimilarFilings":[],"originalDeveloper":"Zhejiang Beta Pharma Inc.","recentPublications":[{"date":"2026 Feb 28","pmid":"41815163","title":"A case report of idiopathic pulmonary fibrosis concurrent with EGFR 19 deletion lung adenocarcinoma.","journal":"Translational cancer research"},{"date":"2026 Feb 25","pmid":"41736521","title":"Epidermal growth factor receptor tyrosine kinase inhibitor for the treatment of non-small cell lung cancer in the past 30 years (1997-2026).","journal":"Chinese medical journal"},{"date":"2026 Feb 23","pmid":"41729955","title":"Efficacy and Safety of Aumolertinib/Icotinib Combination Therapy for Naive EGFR-Mutant NSCLC Patients with Brain Metastases: A Phase I/II Study.","journal":"Neuro-oncology"},{"date":"2026 Mar","pmid":"41707781","title":"Economic value, affordability, and scale-up of adjuvant immunotherapies in lung cancer treatment: From cost-effectiveness decision to budget impact analysis.","journal":"Journal of cancer policy"},{"date":"2025 Nov 20","pmid":"41622936","title":"[A Case of Refractory Pulmonary Enteric Adenocarcinoma with EGFR Sensitive Mutation].","journal":"Zhongguo fei ai za zhi = Chinese journal of lung cancer"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"ICOTINIB","companyName":"Zhejiang Beta Pharma Inc.","companyId":"zhejiang-beta-pharma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"OTHER","regulator":"China Food and Drug Administration (CFDA)","status":"approved","approval_date":null,"mah":"Zhejiang Beta Pharma Inc.","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:10:50.915619+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}